PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-19

Study Completion Date

2022-10-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase 3 clinical trial, randomized, single-center, opened, controlled, to evaluate efficacy and safety of early administration of colchicines in patients older than 60 years, with high risk of pulmonary complications due to coronavirus SARS-CoV2 (COVID-19). An approximately number of 954 subjects meeting all inclusion and none exclusion criteria will be randomized either to receive colchicines or symptomatic treatment with paracetamol during 21 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center

NCT04492358

Covid19

TERMINATED PHASE2/PHASE3

Colchicine in COVID-19: a Pilot Study

NCT04375202

COVID-19

TERMINATED PHASE2

The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention

NCT04326790

Corona Virus Disease 19 (Covid 19)

TERMINATED PHASE2

Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)

NCT04355143

COVID-19

COMPLETED PHASE2

COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19

NCT04363437

Coronavirus Infection

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of the study is to determine whether short term course of colchicines reduces number of deaths due to COVID-19 and severe complications due to the virus in elderly patients with comorbidities.

The secondary objective is to determine the safety of colchicines in this patient population.

Approximately 954 subjects who meet all inclusion criteria and none exclusion criteria will be randomized either to receive colchicines or symptomatic treatment (2:1 allocation ratio) during 21 days. Follow-up assessments will occur every 48 hours and always at day 10, 21 and 61 following randomization for evaluation of the occurrence of any trial endpoints or other adverse events.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV-2 Infection (COVID-19)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Colchicine plus symptomatic treatment (paracetamol).

Patients in this arm will receive study medication colchicines 0.5 mg orally (PO) twice daily for the first 3 days and then once daily for the last 18 days. If a dose is missed, it should not be replaced.

All patients should also receive best symptomatic treatment (mainly paracetamol), based on clinical practice.

Group Type EXPERIMENTAL

Colchicine plus symptomatic treatment (paracetamol)

Intervention Type DRUG

Colchicine plus symptomatic treatment (paracetamol).

Symptomatic treatment

Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).

Group Type ACTIVE_COMPARATOR

Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)

Intervention Type DRUG

Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Colchicine plus symptomatic treatment (paracetamol)

Colchicine plus symptomatic treatment (paracetamol).

Intervention Type DRUG

Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)

Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients of both sexes who are at least 60 years old.
2. Diagnosis of COVID-19 infection in the last 72 hours and confirmed by PCR
3. Patient in outpatient follow-up (not hospitalized or under consideration) or institutionalized in senior centers/residences
4. The patient must possess at least two of the following high-risk criteria

1. 60 years of age or older AND
2. Any of the following: Diabetes mellitus, high blood pressure, known pulmonary disease (including asthma or chronic obstructive pulmonary disease), known heart failure, known coronary disease, bicytopenia, pancytopenia, or the existence of simultaneous neutrophilia and lymphopenia
5. The patient must be able and willing to comply with the requirements of this study protocol.

Exclusion Criteria

1. Hospitalized patient or under immediate consideration of doing so
2. Patient taking colchicine for other indications
3. Patient with history of allergic reaction or sensitivity to colchicine
4. Patient with inflammatory bowel disease, gastric ulcer, chronic diarrhea or malabsorption
5. Patient with pre-existing progressive neuromuscular disease
6. Patient with kidney damage and estimated glomerular filtrate rate \<30 ml/m at 1732
7. Patient undergoing chemotherapy for cancer, including haematological malignancies.
8. Patients being treated with CYP3A4 and/or glycoprotein inhibitor drugs
9. Immunosuppressive treatment
10. History of cirrhosis, chronic active hepatitis, severe chronic disease defined by GOT or GPT values exceeding 3 times the upper limit of normal.
11. If the investigator considers it, for any reason, to be an inadequate candidate.
12. Patient and/or legal representative will not have signed the informed consent form.

Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No